CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 269 enrolled
Drug / intervention
Prednisone +1 moredrug
Likely dose
Prednisone 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00668434
NCT00668434Phase 2Completed
CompareCT.gov

A Corticosteroid Taper for Acute Sciatica Treatment (The ACT FAST Study)

Kaiser Permanente·interventional·Posted Apr 29, 2008·Updated Apr 28, 2015

In Brief

A Phase 2 clinical trial evaluating Prednisone and Placebo for Sciatica. Completed, enrolled 269 participants across 3 sites.

Detailed Summary

Sciatica is a condition that causes a sharp, burning pain in the back, buttock, and leg. The condition is caused by injury to or compression of the sciatic nerve, which is located in the back of the leg. This study will determine the effectiveness of the steroid prednisone in decreasing pain and improving function in people with sciatica.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSciatica
CountriesUnited States
CollaboratorsNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 29, 2008
Enrollment StartNov 1, 2008
Primary CompletionSep 1, 2012
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 18.2 years ago

Interventions

Prednisonedrug

For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.

Placebodrug

Placebo capsules will look the same as the study medication but will not contain active medicine.